Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Fiche du document
1 février 2021
- doi: 10.1084/jem.20192203
- issn: 0022-1007
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1084/jem.20192203
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33156338
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1540-9538
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_75DE24FE756B5
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases Mouse House mice Mus musculus House mouseCiter ce document
E. Lanitis et al., « Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. », Serveur académique Lausannois, ID : 10.1084/jem.20192203
Métriques
Partage / Export
Résumé
Limited clinical benefit has been demonstrated for chimeric antigen receptor (CAR) therapy of solid tumors, but coengineering strategies to generate so-called fourth-generation (4G) CAR-T cells are advancing toward overcoming barriers in the tumor microenvironment (TME) for improved responses. In large part due to technical challenges, there are relatively few preclinical CAR therapy studies in immunocompetent, syngeneic tumor-bearing mice. Here, we describe optimized methods for the efficient retroviral transduction and expansion of murine T lymphocytes of a predominantly central memory T cell (TCM cell) phenotype. We present a bicistronic retroviral vector encoding both a tumor vasculature-targeted CAR and murine interleukin-15 (mIL-15), conferring enhanced effector functions, engraftment, tumor control, and TME reprogramming, including NK cell activation and reduced presence of M2 macrophages. The 4G-CAR-T cells coexpressing mIL-15 were further characterized by up-regulation of the antiapoptotic marker Bcl-2 and lower cell-surface expression of the inhibitory receptor PD-1. Overall, this work introduces robust tools for the development and evaluation of 4G-CAR-T cells in immunocompetent mice, an important step toward the acceleration of effective therapies reaching the clinic.